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AbstrAct
Objective Investigate whether hyoscine patch or 
glycopyrronium liquid is more effective and acceptable to 
treat drooling in children with neurodisability.
Design Multicentre, single-blind, randomised controlled 
trial.
setting Recruitment through neurodisability teams; 
treatment by parents.
Participants Ninety children with neurodisability who 
had never received medication for drooling (55 boys, 35 
girls; median age 4 years). Exclusion criteria: medication 
contraindicated; in a trial that could affect drooling or 
management.
Intervention Children were randomised to receive a 
hyoscine skin patch or glycopyrronium liquid. Dose was 
increased over 4 weeks to achieve optimum symptom 
control with minimal side-effects; steady dose then 
continued to 12 weeks.
Primary and secondary outcomes Primary outcome: 
Drooling Impact Scale (DIS) score at week-4. Secondary 
outcomes: change in DIS scores over 12 weeks, Drooling 
Severity and Frequency Scale and Treatment Satisfaction 
Questionnaire for Medication; adverse events; children’s 
perception about treatment.
results Both medications yielded clinically and 
statistically significant reductions in mean DIS at week-
4 (25.0 (SD 22.2) for hyoscine and 26.6 (SD 16) for 
glycopyrronium). There was no significant difference 
in change in DIS scores between treatment groups. By 
week-12, 26/47 (55%) children starting treatment were 
receiving hyoscine compared with 31/38 (82%) on 
glycopyrronium. There was a 42% increased chance of 
being on treatment at week-12 for children randomised 
to glycopyrronium relative to hyoscine (1.42, 95% CI 
1.04 to 1.95).
conclusions Hyoscine and glycopyrronium are 
clinically effective in treating drooling in children with 
neurodisability. Hyoscine produced more problematic side 
effects leading to a greater chance of treatment cessation.
trial registration numbers ISRCTN 75287237; 
EUDRACT: 2013-000863-94; Medicines and Healthcare 
Products Regulatory Agency: 17136/0264/001-0003
IntrODuctIOn
Drooling saliva is a common problem in children 
with neurodisability.1–3 The negative consequences 
of drooling include skin breakdown on the child’s 
chin and damage to clothing and equipment. 
Children and family members experience social 
embarrassment due to the physical appearance of 
drooling.4–6 Bibs or wristbands may be used to soak 
up saliva and clothing changes with extra washing 
loads are required.4 7 
Anticholinergic medication is used to treat 
problematic drooling. In a UK clinical practice 
survey,8 98% of paediatricians reported using such 
medication: 85% used hyoscine delivered by skin 
patch as first-line treatment and glycopyrronium 
liquid second. Other treatments for drooling are 
used but have drawbacks.9 10 There is inadequate 
evidence about the relative effectiveness of hyos-
cine or glycopyrronium.11 12 Both medications 
have predictable, dose-dependent side effects and 
reported neurological effects.4 As there are limited 
data about how children and parents balance side 
effects against reduction in drooling, it is difficult 
What this study adds?
 ► Hyoscine and glycopyrronium are both clinically 
effective in treating problematic drooling in 
children with neurodisability.
 ► Hyoscine is associated with more problematic 
side effects than glycopyrronium and is less 
likely to be tolerated by children and parents.
 ► Where either medication might be used, 
glycopyrronium should be the medication of 
first choice—the opposite situation to current 
UK prescribing practice.
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What is already known on this subject?
 ► Drooling saliva is common in children with 
neurodevelopmental disorders. Negative 
consequences include skin breakdown, 
dehydration, damage to clothing and equipment 
and social embarrassment.
 ► Most UK paediatricians prescribe hyoscine 
first and glycopyrronium second. There is no 
comparative evidence about the effectiveness, 
side effects or patient acceptability of these 
medications.
 ADC Online First, published on November 30, 2017 as 10.1136/archdischild-2017-313763
Copyright Article author (or their employer) 2017. Produced by BMJ Publishing Group Ltd (& RCPCH) under licence. 
group.bmj.com on December 8, 2017 - Published by http://adc.bmj.com/Downloaded from 
2 Parr JR, et al. Arch Dis Child 2017;0:1–6. doi:10.1136/archdischild-2017-313763
Original article
table 1 Baseline characteristics of the 90 children randomised
characteristic
Hyoscine Glycopyrronium total
n=49 n=41 n=90
Sex
  Female 16 (33%) 19 (46%) 35 (39%)
  Male 33 (67%) 22 (54%) 55 (61%)
  Age at randomisation
  Median (years) 4.9 4.6 4.9
  Range (3.0, 14.5) (3.0, 11.9) (3.0, 14.5)
Weight
  Median (kg) 18.1 16.6 18.1
Range (11.1, 79.4) (10.4, 41.8) (10.4, 79.4)
Children with cerebral palsy 10 (20%) 12 (29%) 22 (24%)
Severity of drooling*
  Saliva usually on clothes 43 (88%) 35 (85%) 78 (87%)
  Saliva usually on face 6 (12%) 6 (15%) 12 (13%)
Baseline Drooling Impact Scale
  n 47 39 86
  Mean (SD) 57.9 (15.5) 52.1 (12.7) 55.3 (14.5)
  Median (Range) 58 (26, 85) 53 (25, 75) 54.5 (25, 85)
 Baseline Drooling Severity and Frequency Scale†
  n 35 33 68
  Mean (SD) 7.6 (1.1) 7.6 (1.1) 7.6 (1.1)
  Median (Range) 8 (5, 9)  (5, 9) 8 (5, 9)
*Stratification factor at randomisation.
†Baseline scores for those whose treatment was tolerated to week-4.
for children, parents and doctors to decide which medication to 
use, at what dose. Comparative effectiveness trials of different 
treatment approaches are needed in child health generally and in 
paediatric neurodisability.13
We report a randomised comparative effectiveness trial 
designed to investigate increasing dosages of medication to treat 
problematic drooling (hyoscine skin patches and liquid glycopy-
rronium). We aimed to identify whether, at maximal tolerated 
dose, one medication achieved a better balance than the other 
between effectiveness and side effects and make recommenda-
tions for future standards of care for children with significant 
drooling.
MetHODs
The Drooling Reduction Intervention (DRI) trial protocol is an 
open access publication.14 Key elements are summarised briefly.
Design
Multisite, prospective, single-blind, pragmatic, randomised 
controlled comparative effectiveness trial of treatment with 
hyoscine skin patch or glycopyrronium liquid for children with 
neurodisability and problematic drooling.
trial population
Ninety children from 15 UK National Health Service (NHS) 
neurodevelopmental teams recruited over 17 months. Inclu-
sion criteria: children with no progressive deterioration of 
neurological function; no previous medical/surgical treatments 
for drooling (treatment naïve); requiring medication to reduce 
drooling; no contraindication to either medication; age >35 
months to <16 years; weight ≥10 kg. Exclusion criteria: Chil-
dren who had received treatments for drooling; parents unable 
to follow study protocol or complete a telephone call in English; 
previous study withdrawal; in a trial of medication that could 
interact with drooling management; pregnant.
Identification and recruitment of participants
Recruitment of participants was by consultant neurodevelop-
mental paediatricians through routine UK NHS care. Written 
consent was taken. Assent was sought from children where 
appropriate. Participants could withdraw and return to usual 
local clinical care.
randomisation and blinding
Participants were randomised using the Newcastle Clinical Trials 
Unit web-based service. Participants were allocated to hyoscine 
or glycopyrronium (ratio 1:1), stratified by recruitment site and 
drooling severity using the modified Mier classification: saliva 
usually on lips and chin or saliva on lips chin and clothes.15 
Medication type was not known to the ‘outcome assessor’.
Intervention
Children received hyoscine patches or glycopyrronium liquid 
according to an escalation protocol.14 16 Medication was 
increased weekly from week-1 to week-4 to the dose needed 
to stop drooling or to the maximum allowed dose or to the 
maximum associated with tolerable adverse effects. There-
after, participants remained on the week-4 medication dose for 
8 weeks.
Children randomised to hyoscine received the following 
regime: week-1: ¼ patch; week-2: ½ patch; week-3: ¾ patch; 
week-4: full patch. The patch was typically placed below an 
ear with an occlusive dressing applied over and replaced every 
3 days, alternating sites to minimise local skin reaction risk. The 
plastic patch backing was cut to expose the prescribed portion 
of the patch; the patch itself was not cut to avoid leakage of 
product from the non-loculated reservoir. Children randomised 
to glycopyrronium liquid received three doses per day: week-1: 
40 µg/kg/per dose; week-2: 60 µg/kg/per dose; week-3: 80 µg/kg/
per dose; week-4: 100 µg/kg/per dose to a maximum 2 mg per 
dose. Medication was given orally or by feeding tube.
Outcome measures
Primary outcome: Drooling Impact Scale (DIS) score at 4 weeks 
(range 0–100, SD 13).17 It is a parent-reported outcome measure, 
addressing psychosocial impacts and drooling itself.
Secondary outcomes: change in DIS and Drooling Severity 
and Frequency Scale (DSFS) scores between baseline, week-4 and 
week-12 and difference between groups in the Treatment Satis-
faction Questionnaire for Medication (TSQM) score at week-4 
and week-12. The DSFS18 captures parent report of drooling 
severity and drooling frequency. The TSQM19 has four domains: 
effectiveness, side effects, convenience and global satisfaction.
Trial procedures
Medication was prescribed locally (see table 114). Parents 
received: medication; parent information sheets; occlusive 
dressings (hyoscine) or syringes (glycopyrronium). Parents 
received telephone calls to week-12 from a trial paediatrician 
with expertise in drooling management (ET/JP/AC). Informa-
tion about drooling reduction and side effects was sought using 
a standardised report form (available from the author). Ques-
tions covered predictable side effects16: unable to use/tolerate 
the patch or medication; skin reactions (hyoscine); constipation; 
dry mouth/respiratory secretions; vision difficulties; urinary 
side effects; skin flushing/dryness; vomiting; seizures; drowsi-
ness; dizziness. Non-predictable side effects were also recorded. 
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Participants with significant side effects had medication 
decreased to the previous dose; briefly interrupted or stopped. 
The trial paediatrician completed with parents the TSQM.
Parents were telephoned by an outcome assessor (SN and LP), 
blind to treatment arm, who completed with parents the DIS 
and DSFS at baseline, week-4 and week-12 or when medication 
stopped. Parents were informed in the information sheet and 
reminded at telephone calls that outcome assessors were blind 
to medication type.
Interviews with children
Children able to self-report were interviewed by ET about their 
experiences of drooling medications after week-12. Children 
were asked: to rate on a five-point scale ‘how bad their drooling 
was currently and before starting medication’; if medication 
helped them and how; how they felt while taking medication. 
Pictures of body parts and home settings assisted discussions.
statistical methods
Statistical analyses were undertaken in Stata20 following a statis-
tical plan agreed before data were unblinded. Analyses were 
based on two populations: intention-to-treat group (ITT) of 
all patients, retaining children in their randomised treatment 
groups; treatment-tolerated group (TT) of all patients who were 
still on their starting treatment at 12 weeks.
The primary analysis of the primary outcome measure used 
the ITT group. DIS scores recorded 26–35 days inclusive from 
the start of treatment were included. If one or two components 
of the child’s DIS score at week-4 were missing, their total DIS 
score was scaled proportionately; if three or more components 
were missing, their DIS score was excluded. DIS scores for the 
two randomised groups are presented with 95% CIs for the 
mean difference between groups. A bias corrected bootstrap 
was applied using 5000 bootstrap replicates. Analysis of covari-
ance was used to compare week-4 DIS scores between treatment 
groups adjusted for the stratification factor of baseline drooling 
severity, reporting the coefficient (SE) for the stratification factor 
and adjusted treatment effect.
Secondary analysis of the primary outcome measure was 
adjusted for the stratification factor baseline drooling severity and 
covariates age, sex and baseline DIS score. Repeated measures 
analysis of variance investigated the DIS over time. Secondary 
outcomes DSFS and TSQM are reported descriptively.
Sample size: The study was powered to detect a clinically 
significant difference of 10 points in mean DIS score at 4 weeks 
between groups, assuming previously reported SD of 13, repre-
senting parents views as the difference between ‘very good to 
excellent’ and ‘good’ in a global rating.17 To detect this difference 
with 90% power and type 1 error of 5%, required a minimum 
of 36 children per group. Inflated for a 20% loss to follow-up 
yielded a target of 90 children.
trial management, quality assurance and regulatory issues
The trial was managed through the Newcastle Clinical Trials 
Unit. Medicines and Healthcare Products Regulatory Agency 
approval was obtained: 17136/0264/001–0003. A Data Moni-
toring Committee monitored efficacy and safety endpoints using 
unblinded interim data and reported to an independent Trial 
Steering Committee.
results
Ninety children were randomised, 55 (61%) boys and 35 girls, 
median age 4 years (range 3–14). Recruitment per site ranged 
from 1 to 15 children (median 6). In 78 children (87%), drooling 
affected their clothing and in 12 drooling only affected the lips 
and face. Forty-nine children were randomised to hyoscine and 
41 to glycopyrronium (table 1). Baseline mean DIS scores were 
similar in both arms (hyoscine 57.9 (SD 15.5, range 26, 85) vs 
glycopyrronium 52.1 (SD 12.7, range 25, 75)). Children’s diag-
noses were: cerebral palsy 22; developmental delay/disorder 22; 
genetic conditions 14; autism spectrum disorder 12; learning/
intellectual disability 10; structural brain disorders 6; Down 
syndrome 5; miscellaneous 14. Three-quarters had multiple 
diagnoses (up to seven per child) and two-thirds took one or 
more medications (up to seven per child).
Following randomisation, 85 children started treatment: 47 
hyoscine, 38 glycopyrronium (figure 1). By week-4 and week-12 
children randomised to hyoscine were less likely be on medi-
cation than children randomised to glycopyrronium due to 
unacceptable side effects (reported below). By week-12, 26/47 
(55%) children starting treatment were receiving hyoscine 
compared with 31/38 (82%) on glycopyrronium. There was a 
42% increased chance of still being on treatment at week-12 
for children randomised to glycopyrronium relative to hyoscine 
(risk=1.42, 95% CI 1.04 to 1.95).
Primary outcome measure
Seventy children (78%) had week-4 DIS assessments at 26–35 
days inclusive. Thirteen children (14%) had assessments outside 
the required window and two started treatment but stopped 
before week-4.
Mean week-4 DIS scores were 32.1 (SD 19.4) in 41 children 
receiving hyoscine and 25.3 (SD 14.1) in 29 children receiving 
glycopyrronium. There was no significant difference in week-4 
DIS scores between treatment groups. Both hyoscine and glyco-
pyrronium led to statistically significant reductions in DIS scores 
from baseline to week-4 (Bonferroni corrected p<0.0001) with 
similar reductions in both treatment arms. Mean change in DIS 
from randomisation to 4 weeks was 25.0 for hyoscine (SD 22.2, 
95% CI 18.0 to 32.0) and 26.6 for glycopyrronium (SD 16.0, 
95% CI 20.5 to 32.7).
The mean week-4 DIS score was higher for hyoscine than for 
glycopyrronium with an unadjusted estimate of the difference in 
mean scores of 6.8 (95% CI −1.6 to 15.3) (table 2, Model 1). 
Children with more severe drooling at baseline tended to have 
higher week-4 DIS scores, mean difference of 5.9 (95% CI −8.0 
to 19.8) (table 2, Model 2). Controlling for drooling severity, age 
at randomisation and baseline DIS score the adjusted estimate of 
the difference in mean week-4 DIS scores between randomised 
groups was 4.0 (95% CI −4.4 to 12.5) (table 2, Model 3).
There was a risk that 4-week data collected just outside the 
26–35-day window (eg, some people were inevitably difficult to 
contact due to illness or holidays) would not be used and might 
influence interpretation. Therefore, a sensitivity analysis of the 
primary outcome at week-4 was conducted, based on the ITT 
group and including those whose DIS had been collected outside 
the protocol window. This did not alter the conclusions.
secondary outcome measures
For the ITT group, mean week-12 DIS scores were 31.0 (SD 
19.3) in 38 hyoscine patients and 23.8 (SD 17.5) in 33 glycopy-
rronium patients. No difference was observed between week-4 
and week-12 DIS scores for either the hyoscine and glycopyrro-
nium groups: mean hyoscine change 1.4 (SD 25.5), mean change 
glycopyrronium −1.1 (SD 15.8) (figure 2). A sensitivity analysis 
compared the TT group week-12 DIS scores for the medication 
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Figure 1 Consort diagram. ITT, intention to treat. 
table 2 Adjusted estimates of the treatment effect of DIS at week-4
coefficient se
95% cI
lower upper
Model 1
  Unadjusted treatment effect 6.8 4.2 −1.6 15.3
Model 2
  Adjusted treatment effect 6.8 4.2 −1.7 15.2
  Severity of drooling:
  Saliva usually only on lips/chin – – –
  Saliva on lips, chin and clothes 5.9 7.0 −8.0 19.8
Model 3
  Adjusted treatment effect 4.0 4.2 −4.4 12.5
  Saliva on lips, chin and clothes 1.6 7.4 −13.0 16.3
  Age at start of treatment 1.2 0.7 −0.2 2.5
  Baseline DIS score 0.3 0.2 −0.02 0.58
DIS, Drooling Impact Scale.
Figure 2 Mean Drooling Impact Scale scores at baseline, week-4 and 
week-12 for the intention-to-treat group (with 95% CI).
and did not alter conclusions. This was important to conduct 
since the ITT group at 12 weeks could include children who had 
stopped their trial medication and been changed to the medica-
tion of the other trial arm by their local paediatrician to whom 
care had been returned.
Mean DSFS scores at baseline were similar (table 1) (mean 
7.5 (SD 1.1) for hyoscine, mean 7.6 (SD 1.1) for glycopyrro-
nium) and were reduced for both hyoscine and glycopyrronium 
at week-4 (mean 5.1 (SD 1.8), 4.7 (SD 1.9), respectively), with 
similar reductions at week-12 (mean 4.7 (SD 1.6), 4.7 (SD 1.9), 
respectively).
There were no observed differences in mean TSQM domain 
scores between hyoscine (n=33) and glycopyrronium (n=31) 
at week-4: Effectiveness (79.5 (SD 17.2), 86.8 (SD 9.8)); Side 
Effects (96.0 (SD 13.4), 98.1 (SD 5.1)); Convenience (79.1 
(SD 15.2), 85.8 (SD 12.0)). A somewhat lower week-4 Global 
score for hyoscine (74.5 (SD 15.6), 86.3 (SD 13.5)) may reflect 
reduced hyoscine compliance. Week-12 scores for all domains 
were similar.
Predictable side effects
Predictable side effects were reported less frequently by 
parents of children who received hyoscine 22/47 (46.8%) 
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than glycopyrronium 24/38 (63.2%). Those most commonly 
reported for hyoscine and glycopyrronium respectively were: 
unwell 14/47 (29.8%) vs 15/38 (39.5%); constipation 5/47 
(10.6%) vs 12/38 (31.6%); excessive drying of respiratory/oral 
secretions 3/47 (6.4%) vs 7/38 (18.4%); skin flushing/dryness 
8/47 (17.0%) vs 3/38 (7.9%). Other side effects were seen in less 
than two children per treatment arm.
Problematic side effects leading to stopping medication
Hyoscine was associated with more problematic predictable side 
effects leading to children stopping medication than glycopyr-
ronium. Seventeen parents from the hyoscine arm reported a 
predictable side effect that led to cessation of their child’s medi-
cation (11 with skin reactions to patches (redness, blistering, 
swelling, skin breakdown, some of which only started after many 
weeks in the trial), one with dry mouth, one with pupil dilation 
and four repeatedly pulled off their patches). This compares to 
only six parents reporting a predictable side effect leading to 
cessation of glycopyrronium (two with dry mouth, two with 
constipation and two with skin dryness or rash).
Children receiving hyoscine also stopped medication due to 
non-predictable side-effects more frequently than those receiving 
glycopyrronium. Seven children on hyoscine stopped medica-
tion (three with unsteady walking, two with hyperactivity, one 
with floppiness, one with increased seizure activity). One child 
on glycopyrronium stopped medication due to hyperactivity. 
Some parents cited more than one side effect as the reason for 
stopping medication.
Interviews with children and young people
Interviews were conducted with two children receiving hyoscine 
and four receiving glycopyrronium. All communicated verbally. 
All rated their drooling as bad or very bad before medication. 
One child stopped taking glycopyrronium at 3 days because 
her mouth dried and she thought she was going to choke when 
eating. The five children still on medication when interviewed 
rated their drooling as ‘good’ or ‘very good’ and said their chin 
was dry and no longer sore and their clothes remained dry. Other 
positive observations were: friends no longer tease me (n=2); 
school work and computers remain dry (n=1); no saliva spray 
when talking (n=1). Negative observations were the hyoscine 
patch caused itching and glycopyrronium having an unpleasant 
taste.
DIscussIOn
The randomised DRI trial is the first to use a protocol with 
standard dose escalation and side effect monitoring, to compare 
directly the effectiveness of hyoscine and glycopyrronium for 
the treatment of drooling in children with neurodisability. For 
both medications, the improvement in the DIS score was statisti-
cally and clinically significant. While hyoscine patches were well 
tolerated by some children, almost half parents stopped medi-
cation (21/47, 45%)—significantly higher than for glycopyrro-
nium which was associated with fewer problematic side effects 
and was better tolerated. Skin reactions to hyoscine and intol-
erance of the patches frequently caused difficulties. Predictable 
and non-predictable side effects made hyoscine less acceptable 
to parents than glycopyrronium whose side effects were self-lim-
iting or could be treated (eg, increasing doses of constipation 
medication). Hyoscine treatment by patch has been favoured by 
some because it is effective and they think it is a more convenient 
method of administration than three times daily oral medica-
tion.8 Further, glycopyrronium has only hitherto been available 
as a 1 mg/5 mL solution with a 28-day shelf life. As there are 
now also 1 mg/mL preparations with a shelf life of 1 year and 
a licensed preparation for children, we think our study shows 
glycopyrronium liquid should be the medication of first choice.
Regarding study strengths, this multicentre, prospective, prag-
matic, randomised, controlled trial recruited children across 
the UK from regions with varying deprivation and population 
characteristics. Paediatricians deliver high-quality assessments 
of children with neurodisability and advise on management.21 22 
Participants in the trial arms were comparable at baseline. Trial 
blinding was effective because none of the parents divulged the 
child’s treatment group to the blinded outcome assessor. Both 
medications are in routine NHS use. Data were systematically 
gathered using methods designed with parents.14 Five out of 90 
(5.5%) of families did not start medication; there was no loss to 
follow-up.
Regarding study limitations, we relied on parent report of 
side effects; in children with limited communication ability, this 
may have underestimated such effects.23–25 The trial was blinded 
where possible; however, parents were not blind to the medica-
tion they received; their experience of medication might have 
affected their responses to outcome assessor questionnaires. 
As the TSQM focuses on information about side effects and 
satisfaction, these data were gathered by the non-blinded trial 
paediatrician; it is possible this could introduce bias. Individual 
diagnostic neurodisability groups were too small for subgroup 
analysis. We recruited families where parents could speak suffi-
cient English by telephone. We are not able to comment on the 
representativeness of the children recruited; however, the range 
of diagnoses, other conditions and other medications received 
was in line with our expectations from clinical practice.
These trial results indicate that where neither medication is 
contraindicated or definitely preferred, glycopyrronium should 
be the drug of first choice. In the future, additional data gath-
ered systematically from clinical samples about the medica-
tions will add to the evidence base. We consider introduction 
of medication using a stepped protocol should be undertaken 
before considering other treatments.10 11 The protocol of weekly 
phone calls for 4 weeks to adjust dosage in the light of drooling 
response and side effects was acceptable to parents and can 
be used by clinical teams (protocol is freely available from the 
corresponding author). Such a protocol should be considered for 
incorporation into guidance for drooling treatment. Evaluation 
of the effectiveness of a telephone delivered stepped protocol 
should be undertaken, to show whether it is feasible and useful 
to clinicians, parents and children in clinical practice.
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